Genentech has reported positive findings from the Phase III IMbrave050 trial of Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) to treat patients with hepatocellular carcinoma (HCC), a type of adjuvant liver cancer.
The results showed that the therapy combination minimised the risk of cancer returning by 28% in comparison with active surveillance at 17.4 months of median follow-up period.
The independent review facility RFS hazard ratio data were also found to be generally consistent across clinical subgroups of the trial.
At 7%, overall survival (OS), a major secondary endpoint, was reported immature at the time of data evaluation.
The safety data for the combination of Tecentriq and Avastin were in line with the well-established safety profile of each of the treatment and with the underlying disease.
The therapy combination was the first treatment in over a decade to significantly advance OS over current standard of care, revealed the IMbrave150 trial.
Genentech chief medical officer and global product development head Levi Garraway said: “Four out of five people with HCC who receive surgery with curative intent may still see their cancer return.
“Thus, an urgent need exists for adjuvant treatments to prevent early recurrence and improve survival rates.
“With Tecentriq plus Avastin already a standard of care in unresectable HCC, we are pleased with the potential of these results and look forward to seeing more mature data.”
With the IMbrave150 trial, Genentech aims to help change and improve fundamental treatment results for liver cancer patients.
The global, multicentre, open-label, randomised trial has been designed to assess the efficacy and safety of adjuvant Tecentriq and Avastin combination, in comparison with active surveillance, to treat HCC patients who are at high risk of recurrence following surgical resection or ablation with curative intent.
